HIV Prevention, Intimate Partner Violence (IPV), PrEP, Women
Conditions
Brief summary
U.S. epidemiological data indicates that Black women are a high-risk HIV disparity group, yet initiation of novel prevention strategies like pre-exposure prophylaxis (PrEP) among this group is stagnant. Socio-structural challenges like intimate partner violence and gendered racism can constrain PrEP access among Black women, but few implementation studies have mitigated these challenges to improve PrEP initiation. The proposed research aims to implement and assess the effectiveness, implementation, and sustainability of a multilevel intervention to increase PrEP initiation among Black women with and without intimate partner violence in Baltimore.
Interventions
BEHAVIORALPeer Navigation Group
Participants randomized to the intervention will receive behavioral lifestyle education on topics related to biomedical HIV prevention. This will include 4 group sessions and 4 one-on-one sessions with a peer navigator.
Sponsors
Johns Hopkins Bloomberg School of Public Health
National Institute on Minority Health and Health Disparities (NIMHD)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* self-identified Black cisgender woman; * self-reported HIV-negative status, and * ≥18 years. * reports unprotected vaginal or anal sex in the past 6 months with a male sexual partner, * have at least one substantial HIV risk factor in the past 6 months according to the 2021 Centers for Disease Control (CDC) PrEP Eligibility Guidelines (i.e., HIV-positive sexual partner, recent bacterial Sexually Transmitted Disease (STD), 2+ sex partners, history of inconsistent or no condom use, commercial sex work, and residing in high HIV prevalence area or network), and * never taken PrEP
Exclusion criteria
* non-English speaking and * currently living with HIV
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PrEP initiation | Post baseline up to 6 months | Self-report of oral or injectable PrEP (Cabotegravir). Assessed from date of the most recent prescription. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PrEP adherence | 2-months post-randomization, 4-months post-randomization, and 6-months post-randomization | Biological assess of tenofovir (TFV) levels in client's urine |
Countries
United States
Contacts
CONTACTTiara C. Willie, PhD, MA
CONTACTProject Director, DrPH
PRINCIPAL_INVESTIGATORTiara C. Willie, PhD, MA
Johns Hopkins Bloomberg School of Public Health
Outcome results
None listed